|
|
| (One intermediate revision not shown.) |
| Line 3: |
Line 3: |
| | <StructureSection load='5cxw' size='340' side='right'caption='[[5cxw]], [[Resolution|resolution]] 1.75Å' scene=''> | | <StructureSection load='5cxw' size='340' side='right'caption='[[5cxw]], [[Resolution|resolution]] 1.75Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[5cxw]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Myctu Myctu]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5CXW OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5CXW FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[5cxw]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Mycobacterium_tuberculosis_H37Rv Mycobacterium tuberculosis H37Rv]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5CXW OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5CXW FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=35P:(2R,4S)-5,5-DIMETHYL-2-{(1R)-2-OXO-1-[(PHENOXYACETYL)AMINO]ETHYL}-1,3-THIAZOLIDINE-4-CARBOXYLIC+ACID'>35P</scene>, <scene name='pdbligand=EPE:4-(2-HYDROXYETHYL)-1-PIPERAZINE+ETHANESULFONIC+ACID'>EPE</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.75Å</td></tr> |
| - | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5crf|5crf]]</td></tr>
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=35P:(2R,4S)-5,5-DIMETHYL-2-{(1R)-2-OXO-1-[(PHENOXYACETYL)AMINO]ETHYL}-1,3-THIAZOLIDINE-4-CARBOXYLIC+ACID'>35P</scene>, <scene name='pdbligand=EPE:4-(2-HYDROXYETHYL)-1-PIPERAZINE+ETHANESULFONIC+ACID'>EPE</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene></td></tr> |
| - | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">ponA1, Rv0050, MTCY21D4.13 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=83332 MYCTU])</td></tr>
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5cxw FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5cxw OCA], [https://pdbe.org/5cxw PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5cxw RCSB], [https://www.ebi.ac.uk/pdbsum/5cxw PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5cxw ProSAT]</span></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5cxw FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5cxw OCA], [http://pdbe.org/5cxw PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5cxw RCSB], [http://www.ebi.ac.uk/pdbsum/5cxw PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5cxw ProSAT]</span></td></tr> | + | |
| | </table> | | </table> |
| | == Function == | | == Function == |
| - | [[http://www.uniprot.org/uniprot/PBP1A_MYCTU PBP1A_MYCTU]] Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits) (By similarity). Has little peptidoglycan hydrolytic activity; however it inhibits the synergistic peptidoglycan hydrolysis of RipA plus RpfB.<ref>PMID:20686708</ref> | + | [https://www.uniprot.org/uniprot/PBP1A_MYCTU PBP1A_MYCTU] Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits) (By similarity). Has little peptidoglycan hydrolytic activity; however it inhibits the synergistic peptidoglycan hydrolysis of RipA plus RpfB.<ref>PMID:20686708</ref> |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 28: |
Line 27: |
| | </StructureSection> | | </StructureSection> |
| | [[Category: Large Structures]] | | [[Category: Large Structures]] |
| - | [[Category: Myctu]] | + | [[Category: Mycobacterium tuberculosis H37Rv]] |
| - | [[Category: Anderson, W F]] | + | [[Category: Anderson WF]] |
| - | [[Category: Endres, M]] | + | [[Category: Endres M]] |
| - | [[Category: Filippova, E V]] | + | [[Category: Filippova EV]] |
| - | [[Category: Joachimiak, A]] | + | [[Category: Joachimiak A]] |
| - | [[Category: Kieser, K]] | + | [[Category: Kieser K]] |
| - | [[Category: Kiryukhina, O]] | + | [[Category: Kiryukhina O]] |
| - | [[Category: Structural genomic]]
| + | [[Category: Rubin E]] |
| - | [[Category: MTBI, Structures of Mtb Proteins Conferring Susceptibility to Known Mtb Inhibitors]]
| + | [[Category: Sacchettini J]] |
| - | [[Category: Rubin, E]] | + | |
| - | [[Category: Sacchettini, J]] | + | |
| - | [[Category: B-lactam]]
| + | |
| - | [[Category: Mcsg]]
| + | |
| - | [[Category: Mtbi]]
| + | |
| - | [[Category: Pbp]]
| + | |
| - | [[Category: Penicillin-binding protein-antibiotic complex]]
| + | |
| - | [[Category: Psi-biology]]
| + | |
| - | [[Category: Structures of mtb proteins conferring susceptibility to known mtb inhibitor]]
| + | |
| Structural highlights
Function
PBP1A_MYCTU Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits) (By similarity). Has little peptidoglycan hydrolytic activity; however it inhibits the synergistic peptidoglycan hydrolysis of RipA plus RpfB.[1]
Publication Abstract from PubMed
Mycobacterium tuberculosis is a human respiratory pathogen that causes the deadly disease tuberculosis. The rapid global spread of antibiotic resistant M. tuberculosis makes tuberculosis infections difficult to treat. To overcome this problem new effective antimicrobial strategies are urgently needed. One promising target for new therapeutic approaches is PonA1, a class A penicillin binding protein, which is required for maintaining physiological cell wall synthesis and cell shape during growth in mycobacteria. Here, crystal structures of the transpeptidase domain, the enzymatic domain responsible for penicillin binding, of PonA1 from M. tuberculosis in the inhibitor-free form and in complex with penicillin V are reported. We used site directed mutagenesis, antibiotic profiling experiments and fluorescence thermal shift assays to measure PonA1's sensitivity to different classes of beta-lactams. Structural comparison of the PonA1 apo-form and the antibiotic-bound form shows that binding of penicillin V induces conformational changes in the position of the loop beta4'-alpha3 surrounding the penicillin binding site. We have also found that binding of different antibiotics including penicillin V positively impacts protein stability; while other tested beta-lactams such as clavulanate or meropenem resulted in destabilization of PonA1. Our antibiotic profiling experiments indicate that the transpeptidase activity of PonA1 in both M. tuberculosis and M. smegmatis mediates tolerance to specific cell wall targeting antibiotics, particularly to penicillin V and meropenem. Because M. tuberculosis is an important human pathogen, these structural data provide a template to design novel transpeptidase inhibitors to treat tuberculosis infections. This article is protected by copyright. All rights reserved.
Crystal structures of the transpeptidase domain of the Mycobacterium tuberculosis penicillin binding protein PonA1 reveal potential mechanisms of antibiotic resistance.,Filippova EV, Kieser KJ, Luan CH, Wawrzak Z, Kiryukhina O, Rubin EJ, Anderson WF FEBS J. 2016 Apr 22. doi: 10.1111/febs.13738. PMID:27101811[2]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Hett EC, Chao MC, Rubin EJ. Interaction and modulation of two antagonistic cell wall enzymes of mycobacteria. PLoS Pathog. 2010 Jul 29;6(7):e1001020. doi: 10.1371/journal.ppat.1001020. PMID:20686708 doi:http://dx.doi.org/10.1371/journal.ppat.1001020
- ↑ Filippova EV, Kieser KJ, Luan CH, Wawrzak Z, Kiryukhina O, Rubin EJ, Anderson WF. Crystal structures of the transpeptidase domain of the Mycobacterium tuberculosis penicillin binding protein PonA1 reveal potential mechanisms of antibiotic resistance. FEBS J. 2016 Apr 22. doi: 10.1111/febs.13738. PMID:27101811 doi:http://dx.doi.org/10.1111/febs.13738
|
